What is Synchron?
Synchron is at the forefront of interventional neuromodulation, developing the world's first motor neuroprosthesis, the Stentrode. This brain-computer interface is currently in clinical trials, with the goal of enabling paralyzed patients to regain functional independence. The company's technology platform, spun out of the University of Melbourne and supported by grants from DARPA and the U.S. Department of Defense, also targets potential treatments for Parkinson's disease, epilepsy, depression, and hypertension through endovascular neuromodulation. The technology has garnered significant attention, including public endorsement from former President Barack Obama for its potential to transform the lives of individuals with disabilities.
How much funding has Synchron raised?
Synchron has raised a total of $50M across 2 funding rounds:
Series A
$10M
Series B
$40M
Series A (2017): $10M with participation from Defense Advanced Research Projects Agency and U.S. Department of Defense
Series B (2021): $40M led by ID8 Investments, General Advance, Shanda Group, Forepont Capital Partners, and Khosla Ventures
Key Investors in Synchron
Defense Advanced Research Projects Agency
The Defense Advanced Research Projects Agency (DARPA) is an agency of the U.S. Department of Defense responsible for the development of emerging technologies for use by the military. Their involvement suggests a focus on advanced, potentially life-saving technologies with significant research and development components.
Shanda Group
Shanda Group is a global investment group with a strong sector focus in leading-edge technology and healthcare, indicating a strategic interest in innovative medical solutions and advanced technological applications.
Forepont Capital Partners
Forepont Capital Partners is a global asset manager specializing in healthcare and life sciences, investing in biotech and medtech start-ups. Their participation highlights a commitment to advancing innovative medical research and therapies.
What's next for Synchron?
With its latest major enterprise-level funding, Synchron is poised to accelerate the clinical development and commercialization of its groundbreaking neurovascular technologies. The substantial capital infusion is expected to fuel further research into its Stentrode device and expand its pipeline of neuromodulation solutions for a range of neurological and psychiatric disorders. This strategic backing signals strong confidence in Synchron's mission to redefine treatment paradigms for debilitating conditions and enhance patient quality of life through advanced bioelectronic medicine.
See full Synchron company page
